Successive infusions of EGFR-CAR-T and CD133-CAR-T immunotherapy showed clinical benefits for the treatment of CC: EGFR-CAR-T therapy had PR for 8.5 months, and CD133-CAR-T therapy achieved PR for 4.5 months (ClinicalTrials.gov Identifier: NCT01869166 and NCT02541370) [133]. Here, EGFR is linked to cholangiocarcinoma.